The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064.
 
Scott Rodig
Consulting or Advisory Role - Bristol-Myers Squibb; Perkin Elmer
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Daniel Gusenleitner
No Relationships to Disclose
 
Donald Jackson
Employment - Bristol-Myers Squibb
 
Evisa Gjini
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Chelsea Jin
Employment - Bristol-Myers Squibb
 
Han Chang
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Scott Lovitch
No Relationships to Disclose
 
Christine Horak
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Altor BioScience; Celldex; CytomX Therapeutics
Honoraria - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche
Consulting or Advisory Role - Abbvie; Altor BioScience; Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Eisai; Genentech; GlaxoSmithKline; Ichor Medical Systems; Lion Biotechnologies; Medivation; Merck; Merck; Nektar; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Daiichi Sankyo; Genentech; GlaxoSmithKline; Lion Biotechnologies; Merck; Merck; Novartis; Pieris Pharmaceuticals; Roche
 
Margaret Ann Shipp
Honoraria - AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Merck; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Merck; Takeda
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Consulting or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche